Business

Immutep (ASX: IMM) share price rises in the momentum of clinical trials in 2009

Image Source: Getty Images

Stocks of clinical biotechnology companies Immutep Ltd (ASX: IMM) In the afternoon trading, it rose 2.5% to 62 cents per share.

Immutep’s stock price is Today’s annual report release, Some investment highlights are observed.

Here is a detailed analysis of the key data points in Immutep’s annual report.

Lead drug candidates begin to gain momentum

Immutep is characterized as “a leader in the development of LAG-3 immunotherapeutic products for cancer and autoimmune diseases”.

“Lymphocyte activation gene 3”, or LAG-3 for short, plays an important role in the immune system for tumor formation.

It was actually discovered in 1990 by Immutep’s current Chief Scientific Officer, Frédéric Triebel, and is now in the spotlight in the oncology community.

Immutep currently has four drug candidates based on the LAG-3 hypothesis, each with a different mechanism of action, according to the annual report.

Its main candidate, known in one form as IMP321, is in late clinical development for cancer treatment.

The second candidate, IMP761, is currently undergoing preclinical development for the treatment of autoimmune disorders, along with two clinical programs with “major pharmaceutical partners.”

Immutep felt the most tailwind in 2009 in the LAG-3 domain.

In particular, the company has conducted several clinical trials of the IMP321 (Phase I, II, or IIa) throughout the year.

For example, we have launched a clinical trial with a major pharmaceutical company. Merck & Co Inc When Merck KGaA Investigate IMP321 as a combination therapy in various forms of cancer.

In one of these studies, the TACTI-002 Phase II study, researchers found the safety and efficacy of IMP321 in combination with Merck’s KEYTRUDA label to treat certain types of lung and head and neck cancer. I am investigating.

Further takeout from Immutep’s annual report

Separately, the company also advised plans to launch a new Phase III clinical trial in June.

We plan to evaluate IMP321 in combination with chemotherapy in patients with metastatic breast cancer.

Phase III trials are generally one of the final stages of clinical trials in which a drug must pass before commercialization is approved.

A large sample population across many jurisdictions is needed to obtain the most accurate possible data on dosages, side effects, etc.

Judging from the readings so far, each study has produced promising results, and Immutep’s candidate drugs are well supported in terms of safety and efficacy.

From its annual report, Immutep’s formulation is effective in 10 clinical trials scattered throughout the world.

In addition to trials, the company is also working on several licensing programs. Novartis, GlaxoSmithKline, When Laboratory Corporation of America Holdings For that LAG-3 product.

Investors who want to know more about the company’s performance can refer to its annual financial report for fiscal year 2009, which was released in August. Found here..

Immutep stock snapshot

Immutep’s share price has recorded a return of almost 50% since January 1st this year, showing a very large performance since the beginning of the year.

Over the last 12 months, it has significantly exceeded the benchmark, surpassing 138%. NS& P / ASX200 Index (ASX: XJO) At the same time, a return of about 21%.

Immutep (ASX: IMM) share price rises in the momentum of clinical trials in 2009

Source link Immutep (ASX: IMM) share price rises in the momentum of clinical trials in 2009

Related Articles

Back to top button